ABCG2 is a member of the adenosine triphosphate (ATP)-binding cassette family of multidrug transporters associated with resistance of tumor cells to many cytotoxic agents. Evaluation of modulators of ABCG2 activity has relied on methods such as drug sensitization, biochemical characterization, and transport studies. To search for novel inhibitors of ABCG2, a fluorescent cell-based assay was developed for application in high-throughput screening. Accumulation of pheophorbide a (PhA), an ABCG2-specific substrate, forms the basis for the assay in NCI-H460/MX20 cells overexpressing wild-type ABCG2. Treatment of these cells with 10 µM fumitremorgin C (FTC), a specific ABCG2 inhibitor, increased cell accumulation of PhA to 5.6 times control (Z′ 0.5). Validation included confirmation with known ABCG2 inhibitors: FTC, novobiocin, tariquidar, and quercetin. Verapamil, reported to inhibit P-glycoprotein but not ABCG2, had insignificant activity. Screening of a library of 3523 natural products identified 11 compounds with high activity (≥ 50% of FTC, confirmed by reassay), including 3 flavonoids, members of a family of compounds that include ABCG2 inhibitors. One of the inhibitors detected, eupatin, was moderately potent (IC 50 of 2.2 µM) and, like FTC, restored sensitivity of resistant cells to mitoxantrone. Application of this assay to other libraries of synthetic compounds and natural products is expected to identify novel inhibitors of ABCG2 activity.
INTRODUCTION
A BCG2, ALSO KNOWN AS BREAST CANCER RESISTANCE PROTEIN (BCRP) or mitoxantrone resistance protein (MXR), is a member of the adenosine triphosphate (ATP)-binding cassette (ABC) family of transporters. [1] [2] [3] [4] ABCG2 is known to confer resistance to a wide range of chemotherapeutic agents such as mitoxantrone, topotecan, irinotecan, flavopiridol, and methotrexate, thus making it a potential mediator of drug resistance in cancer. 3 Transport of natural substrates, among which are plant polyphenols, 5, 6 may reflect a physiologic function of ABCG2 in normal cells. 1 ABCG2 is highly expressed in normal and cancer stem cells. [2] [3] [4] Although the clinical relevance of ABCG2 has yet to be established, it does appear to play a role in drug resistance in acute myelogenous leukemia, although conflicting data exist. 3 In addition, ABCG2 expression has been reported in a wide variety of untreated human solid tumors. 7 ABCG2 has also been shown to affect the oral absorption of substrate drugs such as topotecan. 8 Inhibition of ABCG2 increases systemic exposure to topotecan in patients, confirming its effect on drug pharmacokinetics. 9 Thus, the development of ABCG2 inhibitors may have oncologic as well as pharmacologic applications.
A fluorescent chlorophyll derivative, pheophorbide a (PhA), 6,10 has recently been reported to be a specific substrate for ABCG2. 6, 10, 11 Accumulation of PhA in cells results in increased cell-associated fluorescence intensity while having no effect on the fluorescence properties of the molecule. This has formed the basis of flow cytometry assays of ABCG2 activity in cells selected for overexpression of wild-type or mutant ABCG2. 6, 11 It may therefore be possible to develop a high-throughput assay for inhibitors of ABCG2 activity based on fluorescent measurement of cellassociated PhA. In contrast to related ABC transporters such as Pglycoprotein, few if any clinically useful inhibitors of ABCG2 activity have been developed. 10, 12 Availability of additional specific inhibitors of ABCG2 activity would be of obvious utility as both therapeutic and research reagents. This report describes development, optimization, and validation of a unique PhA accumulation assay for use in a multiwell format for identification of ABCG2 inhibitors. This assay is highly reproducible, sensitive, robust, and suitable for automation in a high-throughput environment as demonstrated by identification of putative ABCG2 inhibitors in a library of natural products.
MATERIALS AND METHODS

Materials
Pheophorbide a was obtained from Frontier Scientific (Logan, UT). Fumitremorgin C (FTC) and pure natural products were provided by the Drug Synthesis and Chemistry Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute (Frederick, MD). Tariquidar (XR9576) was provided by Xenova Research (Slough, Berkshire, UK). PhA and FTC were dissolved in DMSO at 25 mM and 10 mM, respectively, and aliquots stored light protected at -20°C. Other inhibitors and test samples were stored at -20°C at 1 to 10 mM in DMSO. Black-wall, clear-bottom 384-well polylysinecoated assay plates were obtained from Corning (Corning, NY). Cell culture media were from Invitrogen (Carlsbad, CA) and fetal bovine serum (FBS) from Hyclone (Kansas City, MO). Mitoxantrone and other chemicals were obtained from Sigma (St. Louis, MO).
Cell culture conditions
NCI-H460 human lung non-small-cell carcinoma cells (National Cancer Institute, Frederick, MD) previously selected for overexpression of wild-type ABCG2 13 were maintained in RPMI 1640 supplemented with penicillin, streptomycin, 10% FBS, and 20 nM mitoxantrone (NCI-H460/MX20). 13 Medium was removed and cells grown in the same medium in the absence of mitoxantrone for 5 to 30 days before assay. Subconfluent cultures were fed the day before harvesting for assay. For mitoxantrone sensitivity studies, parental NCI-H460 cells with low ABCG2 expression 13 were maintained in the same medium but without mitoxantrone. Cells were trypsinized, resuspended in the medium, transferred to 384-well assay plates (40 µL/well), and allowed to attach (37°C, incubator) for ≥ 4 h. Expression levels and functionality of ABCG2 in mitoxantrone-selected and parental NCI-H460 cells are discussed in Robey et al. 13 and Zhou et al. 14 
Fluorescent PhA accumulation assay
FTC, a potent and specific inhibitor of ABCG2 activity, 15 was used as a positive control for assay development and optimization. PhA and FTC (or other compounds) were diluted to 10× final concentration in Ca 2+ /Mg 2+ -free phosphate-buffered saline (PBS; BioWhittaker, Walkersville, MD). PhA (5 µL/well) was added, immediately followed by FTC, DMSO control, or test compound (5 µL/well). For most experiments, final DMSO concentrations ranged from 0.1 to 0.2% (v/v). Cells were incubated at 37°C for 2 to 20 h, medium was removed, and plates were washed (5× 100 µL per well) with PBS containing Ca 2+ and Mg 2+ (Quality Biological, Gaithersburg, MD). The wash step was necessary to reduce background fluorescence due to PhA in the medium (data not shown) as well as to remove any interfering fluorescent test compounds. Fluorescence (in relative fluorescence units or RFU) was read using a Tecan Safire fluorescence plate reader in bottom read mode, 395 nm excitation, 670 nm emission.
Mitoxantrone sensitivity
For ABCG2 inhibitors identified by screening, further analysis included evaluation of the effect of these compounds on sensitivity of ABCG2-overexpressing (NCI-H460/MX20) and parental cells (NCI-H460) to mitoxantrone. Cells were maintained and plated as described in 384-well plates at 10,000 cells/well. After 2 to 4 h, 0 or 1 µM inhibitor was added followed immediately by PBS, 10 µM, or 30 µM mitoxantrone (final concentrations). Cell numbers were evaluated 2 days later by XTT assay. 16 
Assay performance
Signal-to-noise (S/N) ratio, signal-to-background (S/B) ratio, and Z′ values were calculated as described by Zhang et al. 17 Background was defined as cell-associated fluorescence after incubation in the presence of PhA and negative control (DMSO).
Data analysis
Positive (10 µM FTC) and negative (DMSO) controls (16 wells each) were included in each plate for screening, and data for test compounds were normalized to 10 µM FTC response: (RFU test compound -RFU ave background )/(RFU ave 10 µM FTC -RFU ave background ) × 100%. For confirmation of activities, compounds identified as hits in screening (i.e., ≥ 50% of FTC response) were reassayed in quadruplicate and results analyzed by calculation of confidence intervals for reassay data. 18 A "confirmed hit" was defined as a compound for which reassay showed ≥ 50% of FTC response at a 95% confidence interval. Apparent IC 50 values were calculated using SigmaPlot (SPSS, Inc., Chicago) 4-parameter logistic nonlinear regression analysis. Unless otherwise noted, all data are presented as mean ± standard deviation.
RESULTS
Assay optimization
In development of the assay for screening applications in a 384well format, optimization focused on maximizing S/B for FTC. Variation of several assay parameters led to the following optimal conditions: Once these conditions were defined, each parameter was systematically varied to understand the range of acceptable assay conditions. S/B values for 10 µM FTC were within 6% of that obtained under optimal conditions for 10,000 to 20,000 cells/well, 0.5 to 2 µM PhA, and 16 to 20 h incubation. The plates could be read up to 3 h after completion of the PBS wash without significant loss of apparent activity (within 5% of the results obtained when read immediately). Similarly, although the presence of 1% DMSO (highest concentration tested) slightly increased both background fluorescence and fluorescence after 10 µM FTC treatment, S/B was relatively unaffected (< 10% lower than under standard conditions). These results suggest that minor variations in timing, cell counts, and so on from plate to plate have minimal effects on results of the assay. Figure 2 shows dose-response curves for FTC (4 independent assays on separate days). Average IC 50 = 0.79 ± 0.01 µM. Error bars are not shown in Figure 2 to more easily visualize consistency of response. Experiment-to-experiment variation of activity was ≤ 5.5% for every concentration tested. Stability of the response to FTC suggests consistent ABCG2 expression from batch to batch and over time in culture for NCI-H460/MX20 cells.
Application of assay to known compounds
A variety of other compounds have been described as inhibitors of multidrug transporter activity, some with inhibitory activity against ABCG2 and others that are reported to not affect ABCG2 (see Dean et al., 2 Doyle and Ross, 3 A B C cussions of ABCG2 substrates and inhibitors). To assess the validity of this assay, several of these compounds were tested. Results are shown in Table 1 . Six of the compounds (estradiol, estrone, novobiocin, quercetin, reserpine, and XR9576), in addition to FTC, have been previously reported to inhibit ABCG2 activity in 1 or more cell/assay systems. For some of these compounds, IC 50 values were estimated from dose-response curves: estrone, 10.7 µM; novobiocin, 12.6 µM; reserpine, 11.8 µM; and XR9576 (tariquidar), 3.2 µM. For each of these inhibitors, the calculated IC 50 value represents half of the maximal inhibition obtainable for that inhibitor. Note that, except for novobiocin, none of these achieves the same level of inhibitory activity as obtained with FTC. For the remainder, IC 50 values could not be estimated because cellassociated fluorescence continued to increase at the highest concentration tested or compounds were cytotoxic at high concentrations ( Table 1) . By contrast, etoposide and verapamil have been identified as inhibitors of other multidrug resistance proteins but not ABCG2. Neither compound showed significant activity in this assay (< 10% of FTC response).
Repeatability of assay
To assess repeatability of the assay in a screening environment, 1280 compounds randomly chosen from a synthetic compound library obtained from ChemBridge (San Diego, CA) were independently assessed on 2 days. Results appear in Figure 3 . The slopes of the curves in Figure 3A (fluorescence) and 3B (normalized to FTC) are 0.80 and 0.98, respectively. Correlation coefficient was 0.8 for both plots. Average difference between the 2 determinations (normalized) was 3.9%.
Assay repeatability was further assessed on the optimized assay by monitoring S/B and Z′ during development and screening of natural products. Raw data (RFU) for controls were also compared to assess well-to-well variability and plate-to-plate variability within a single day's experiments. Within-plate well-to-well variability averaged 11.5% and 12.2% for negative (DMSO) and positive (10 µM FTC) controls, respectively, with average Z′ of 0.5 and average S/N of 44 (n = 64 plates). Same-day plate-to-plate variation of S/B ratio averaged 4.7% (n = 11 days for which ≥ 3 plates were run). Overall, S/B average was 5.6 ± 0.9 (n = 64 plates).
Screening and analysis of hits from pure natural product library
A library of 3523 pure natural products was screened at 10 µM. Of 19 primary hits (≥ 50% of FTC activity), 1 showed high intrinsic fluorescence (data not shown), and 11 others were confirmed by reassay. Where sufficient material was available for further analysis, 2 additional assays were performed: dose-response curves for PhA accumulation and sensitization of cells to mitoxantrone cytotoxicity. Among the compounds identified as Figure 4 . Insufficient material was available for these assays for the other 2 flavonoids identified and confirmed as inhibitors. Eupatin had an IC 50 of 2.23 ± 0.25 µM (Fig.  4) . The small decrease in activity above 10 µM is probably due to cytotoxicity at high concentrations. Figure 5 shows results of a 48h cytotoxicity assay with mitoxantrone and either eupatin or FTC. Parental cells (NCI-H460, low ABCG2 expression 13 ) were sensitive to mitoxantrone (28% survival in 30 µM mitoxantrone). By contrast, ABCG2-expressing cells (NCI-H460/MX20) were somewhat resistant to mitoxantrone (52% survival in 30 µM mitoxantrone). Addition of FTC or eupatin at 1 µM (along with 30 µM mitoxantrone) to ABCG2-overexpressing cells further reduced cell survival to 21% and 25% of control, respectively. Eupatin alone was not cytotoxic (88% of control at 1 µM), nor did it increase sensitivity of parental cells to mitoxantrone.
DISCUSSION
PhA, recently shown to be an ABCG2-specific substrate, 6,10,11 along with FTC, an ABCG2-specific inhibitor, 15 were used to develop a high-throughput screening assay for inhibitors of ABCG2 activity. The assay has proved to be very robust; S/B ratios (for 10 µM FTC compared to DMSO controls) were essentially unchanged over a wide range of conditions ([PhA], cell number, incubation time, etc.). The signal is also stable for at least 3 h after washing to stop PhA accumulation. Extremely precise timing and coordination of assay steps are therefore not required. High sensitivity and high reproducibility were demonstrated, and activity could be reliably measured at levels as low as 25% of maximal FTC response. The combination of high S/B ratio and low variability results in high confidence in the ability of this assay to detect compounds with ABCG2 inhibitory activity, as reflected by the excellent 17 Z′ value (0.5) in a screening configuration. Repeat assays of the same samples (see Fig. 3 ) also confirm reproducibility and suggest that the likelihood of spurious results (i.e., unrepeatable activity) is low.
In this assay, FTC potency (IC 50 of 0.8 µM) was roughly comparable to values reported in the literature from drug transport or biochemical (ATPase) assays (K i or IC 50 values of 0.3-1.3 µM). 13, [19] [20] [21] Results from testing the assay on a number of other known inhibitors of ABCG2 and/or other ABC transporters further confirm the validity of the assay for measuring activity of ABCG2 inhibitors. Relative effects and potencies of various inhibitors of ABCG2 are difficult to compare to those reported in the literature in that a wide variety of quantitative and semi-quantitative assays have been used to evaluate potential inhibitors and substrates. For example, cyclosporin A has been variously reported to inhibit 19 or not inhibit 22 ABCG2 in biochemical assays and to have no effect on transport activity. 11 Results presented in Table 1 suggest that cyclosporin A may be a moderate inhibitor of ABCG2 transport activity. In the assay described here, for some compounds, it was ABCG2-overexpressing NCI-H460 cells or parental cells with low ABCG2 expression ("ABCG2(-) cells") were plated and incubated in the presence or absence of mitoxantrone with or without 1 µM fumitremorgin C (FTC) or 1 µM eupatin, as described in the Methods section. After 2 days, cell growth/viability was assessed using the XTT assay. 16 Results are normalized for each cell line to untreated controls. Error bars represent standard deviation (n ≥ 3) or range (n = 2 for eupatin-treated cells). *p < 0.05. **p < 0.001 (ANOVA) compared to phosphate-buffered saline (PBS) at the same mitoxantrone concentration. not possible to achieve the concentrations previously reported. At 100 µM, cyclosporin A, etoposide, and tariquidar (XR9576) proved to be cytotoxic to NCI-H460 cells in 18 h. In this assay, cytotoxic materials that also inhibit ABCG2 activity would give false-negative results. However, the pattern of activity that has emerged generally matches activities previously reported, suggesting that this assay can measure activities of ABCG2 inhibitors (e.g., novobiocin, 23, 24 estradiol, 24 estrone, 24, 25 quercetin, 5, 26, 27 reserpine, 28 XR9576 [tariquidar], 11 FTC) while showing minimal activity for noninhibitors (e.g., etoposide, 11 verapamil 11,19 ).
An important difference between the assay described in this report and the previously described use of PhA for probing ABCG2 activity 11 is in incubation times. The previous report assessed cellassociated fluorescence (by flow cytometry) over a short time scale (1 h), whereas maximal effects of FTC in this report required overnight incubation. Although the differences in cell-associated fluorescence in cells treated with or without FTC were detectable and significant (p < 0.001) as early as 2 h (Fig. 1A) , overnight incubation was required to obtain Z′ values of 0.5 (i.e., in the "excellent" range for a screening assay 17 ). Extended incubation times may also account for the lower PhA concentration found to be optimal in this assay as compared to the flow cytometry-based assay where 10 µM was used in some applications. 11 PhA can be photoactivated, resulting in cytotoxicity. 29 Although care was taken to reduce exposure to light, it is likely that the decrease in apparent FTC response at 5 µM (Fig. 1C) is due to toxicity of the PhA. The difference in incubation times may also account for the difference in results observed with cyclosporin A (i.e., a longer time of incubation may be required for accumulation of sufficient PhA to see an effect). Thus, weakly active compounds may be detected in this assay that would be missed in an assay that requires higher potency over a shorter time period.
Longer incubation times may also result in a difference in the phenomena actually being measured. Unlike flow cytometry assays, 30 the assay described here will not distinguish between uptake and efflux. However, long incubation times may be an advantage in selecting for hits that have long-lived activity. More important, longer incubation times will select against cytotoxic compounds that also inhibit ABCG2 (false negatives in this assay) that would be detectable in a short-term transport or biochemical assay. These considerations may affect how data are interpreted and how hit compounds are confirmed (e.g., flow cytometry assay as well as biochemical and drug sensitivity assays).
As optimized, this assay is amenable to high-throughput screening applications for identification of ABCG2 inhibitors. The assay is also appropriate for the establishment of relative potencies of active compounds. Potential pitfalls include the possibility of false positives due to highly fluorescent compounds (particularly in natural products). However, the large Stokes shift (395-670 nm) for pheophorbide a in this application and the requirement for washing plates minimize this possibility. Just as false-negative re-sults may be obtained with cytotoxic compounds, pore-forming proteins or detergents that inhibit ABCG2 would be expected to yield false-negative results in that they would allow ABCG2independent leakage of PhA. Finally, although the assay is configured to only detect materials that block ABCG2, mechanism of action is not limited (including nonspecific protein-binding effects) nor is specificity ensured. Because ABCG2 activity is dependent on ATP hydrolysis, compounds that affect ATP synthesis and accumulation could also appear as false positives. As with kinetics, these issues can be easily resolved by secondary assays and specificity studies with other drug transport proteins.
Application of this assay in screening natural products identified several possible ABCG2 inhibitors active at low micromolar concentrations. The hit definition used in this assay (i.e., a substance giving ≥ 50% of FTC response) was chosen to limit hits to those compounds with relatively high activity. If less active compounds are desired, the assay is sufficiently reliable to reduce the hit cutoff value to as low as 25% (see Fig. 2 ). Screening results with natural products further validated the screening assay. Interestingly, 3 of the hit compounds were flavonoids, a family of compounds previously reported to include a number of potent ABCG2 inhibitors. 26, 27, 31, 32 Note that only relatively highly active flavonoids would be scored as hits in this assay. For example, 10 µM quercetin only showed 32% of FTC activity ( Table 1) . Quercetin was present in the library screened and, as expected, was not identified as a hit in screening at 10 µM using 50% of FTC response as a hit cutoff. Structures (available via the NCBI PubChem database) of the compounds identified appear to be generally consistent with structure-activity relationships previously described for flavonoids. 26, 27, 31, 32 The ability of hit compounds to at least moderately sensitize ABCG2-expressing cells to mitoxantrone supports the contention that the accumulation of PhA in the screening assay reflects functional effects on ABCG2 activity.
Further analysis of the compounds identified here as well as those resulting from additional screening is expected to yield significant new ABCG2 inhibitors. Despite the discovery of novel ABCG2 inhibitors, it is possible that mutations in the ABCG2 gene may ultimately lessen their efficacy. This is true for Pglycoprotein, where a glycine to valine change at amino acid 185 resulted in increased colchicine resistance 33 as well as decreased sensitivity to the Pgp inhibitor verapamil. 34 Mutations at amino acid 482 of ABCG2 have also been shown to affect inhibitor efficacy. Replacing the arginine in wild-type ABCG2 with a threonine or glycine has been shown to affect sensitivity to the ABCG2 inhibitors novobiocin and biricodar as well as the taxane derivatives ortataxel and tRA96023. 24, 35, 36 Although these drug-induced mutations have profound effects on the noted inhibitors, they have yet to be described clinically. Availability of new inhibitors in multiple chemical classes will be useful in understanding the biochemical, physiologic, and clinical implications of ABCG2 mutations as well as providing insights into ABCG2 function.
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